The Valley Desk

ArticleCancer immunology researchPublished

Topical Resiquimod Elicits Systemic Protection and Improves Anti-PD-1 Therapy in Melanoma via Priming of CD8+ T Cells

Read the publication ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Perelman School of Medicine, University of Pennsylvania, The Wistar Institute. Affiliation source

Publication record

Type
Article
Venue
Cancer immunology research
Published
Subject terms
CD8-Positive T-Lymphocytes; Animals; Mice, Inbred C57BL; Humans; Mice; Melanoma, Experimental; Imidazoles; Administration, Topical; Female; Programmed Cell Death 1 Receptor; Immune Checkpoint Inhibitors; Toll-Like Receptor Agonists
PubMed ID
42275481
Added to directory
Source checked

Report a correction or request removal